Omnipod product platform
Revenue Exposure
Nearly all company revenue derives from the Omnipod product platform; success in marketing/selling it determines financial results.
Relevance 100·Dependency 100·Confidence 99
Source evidence
“We expect to continue to derive nearly all our revenue from our Omnipod product platform.”
Omnipod Products
Revenue Exposure
Omnipod products generate nearly all revenue: $2,674.0M of $2,708.1M total in 2025
Relevance 100·Dependency 99·Confidence 98
Source evidence
“Total Omnipod Products2,674.0 2,032.7 31.6 %1.2 %30.3 %”
Third-party payors (Medicare, Medicaid, private insurers)
Customer Exposure
Sales are limited unless third-party payors pay a substantial portion of the sales price; contracts terminable without cause, and legislative changes could affect demand and pricing.
Relevance 95·Dependency 90·Confidence 95
Source evidence
“We expect that sales of our Omnipod products would be limited if a substantial portion of their sales price is not paid for by third-party payors”
Distributors A, B, C
Customer Exposure
Three distributors each represent 25%+ of 2025 revenue (78% combined), concentrating revenue and receivables risk.
Relevance 90·Dependency 75·Confidence 95
Source evidence
“Distributor A27%28%28%
Distributor B26%26%24%
Distributor C25%21%19%”
semiconductor chips
Supplier Dependency
Single-sourced semiconductor chip types embed into Omnipod products; supply disruption could halt manufacturing and sales.
Relevance 85·Dependency 80·Confidence 95
Source evidence
“Supply chain disruptions, supplier shortages, logistic delays, or quality problems could result in manufacturing delays, increased costs, or a possible loss of sales”
Medicare / Medicaid regulation
Regulatory Exposure
Compliance with Medicare/Medicaid regulations is subject to review by OIG, CMS, and DOJ; legislative changes affecting Medicare, Medicaid, and the ACA could adversely affect demand and pricing.
Relevance 85·Dependency 75·Confidence 94
Source evidence
“we anticipate that recently enacted and proposed legislative changes affecting Medicare, Medicaid, and the Affordable Care Act may impact healthcare coverage, which, if implemented could adversely affect both demand for and pricing of our products”
EU Medical Device Regulation (MDR)
Regulatory Exposure
CE Mark under MDR and UKCA enables EU/UK distribution of Omnipod 5 and DASH; Classic Omnipod MDD route ends in 2027, creating a transition deadline.
Relevance 80·Dependency 75·Confidence 97
Source evidence
“can continue to sell Classic Omnipod through 2027 in the European Union and in other countries that recognize the CE Mark”
Dexcom, Inc.
Technology Dependency
Omnipod 5 integrates with Dexcom G6 and G7 CGMs; CGM is sold separately by third parties
Relevance 80·Dependency 65·Confidence 95
Source evidence
“The Pod currently integrates with Dexcom, Inc.’s G6 and G7 CGMs and with Abbott Diabetes Care, Inc.’s (“Abbott”) FreeStyle Libre 2 Plus sensor”
Medtronic Diabetes
Competitive Exposure
Medtronic Diabetes is a named established insulin pump competitor (division being spun out); superior competing products could inhibit ability to compete.
Relevance 80·Dependency 60·Confidence 95
Source evidence
“We compete with established companies that produce insulin pumps, such as Medtronic Diabetes, a division of Medtronic plc”
Tandem Diabetes Care Inc.
Competitive Exposure
Tandem Diabetes Care is a named established insulin pump competitor; competitor innovations or pricing changes could create pressure.
Relevance 75·Dependency 55·Confidence 95
Source evidence
“Tandem Diabetes Care Inc., as well as emerging companies like Beta Bionics Inc.”
Amgen (Neulasta Onpro Drug Delivery agreement)
Revenue Exposure
Substantially all commercialized non-insulin Drug Delivery revenue comes from a customized Pod for Amgen's Neulasta Onpro kit under an agreement expiring December 2028; termination would negatively impact financial results.
Relevance 70·Dependency 85·Confidence 95
Source evidence
“if our agreement with Amgen is terminated or not renewed, our financial results could be negatively impacted”
Abbott Diabetes Care, Inc.
Technology Dependency
Omnipod 5 integrates with Abbott's FreeStyle Libre 2 Plus in various markets; integrating Libre 3 Plus; also used in RADIANT study
Relevance 70·Dependency 55·Confidence 93
Source evidence
“with Abbott’s FreeStyle Libre 2 Plus sensor in Australia... We are currently working to integrate Omnipod 5 with Abbott’s FreeStyle Libre 3 Plus”
GLP-1 drugs
Revenue Exposure
SGLT2 inhibitors and GLP-1 drugs are alternatives in type 2 diabetes management before insulin therapy, affecting future insulin-dependent patient funnel.
Relevance 70·Dependency 40·Confidence 85
Source evidence
“medications, both oral and injectable, including SGLT2 inhibitors and GLP-1 drugs”
Malaysia
Manufacturing Dependency
New manufacturing plant in Malaysia began production in 2024, supporting global supply
Relevance 65·Dependency 55·Confidence 94
Source evidence
“We began producing product at our new manufacturing plant in Malaysia in 2024”
GLP-1 class drugs
Demand Driver
Increased availability and adoption of GLP-1 drugs may delay type 2 diabetes progression in obese patients, potentially reducing future demand for Omnipod products.
Relevance 65·Dependency 40·Confidence 90
Source evidence
“increased availability and adoption of the GLP-1 class of drugs may delay the progression of type 2 diabetes in obese patients”
Privacy/data protection laws (HIPAA, CCPA/CPRA, GDPR, EU AI Act)
Regulatory Exposure
Complex evolving privacy, data protection, and AI regulations (including EU AI Act phased through August 2026) could result in legal claims, monetary penalties, and increased operating costs.
Relevance 60·Dependency 55·Confidence 93
Source evidence
“If we fail to comply with these standards, we could be subject to criminal penalties and civil sanctions, including significant fines and penalties.”
Tariffs
Regulatory Exposure
Elimination of current medical device tariff exemption would materially impact results in future years
Relevance 60·Dependency 40·Confidence 88
Source evidence
“should the exemption that is currently in place for certain medical devices be eliminated, tariffs would have a material impact on our results of operations in future years”
Drug Delivery product line
Revenue Exposure
Drug Delivery depends on one pharmaceutical customer with firm purchase commitments; inventory has no alternative use, recognized over time.
Relevance 55·Dependency 60·Confidence 90
Source evidence
“the product is produced pursuant to the customer’s firm purchase commitments, the Company has an enforceable right to payment for performance completed to date, and the inventory has no alternative use to the Company”
customer pricing incentives
Cost Driver
Chargebacks, distributor fees, returns, discounts, and financial assistance provisions reduce transaction price and thus net revenue.
Relevance 55·Dependency 45·Confidence 85
Source evidence
“These fees are not in exchange for a distinct good or service and therefore are recognized as a reduction of the transaction price.”
Costa Rica
Manufacturing Dependency
Investing in a new manufacturing plant in Costa Rica to support continued growth
Relevance 55·Dependency 40·Confidence 90
Source evidence
“are already investing in another manufacturing plant in Costa Rica to support our continued growth”
Substantially all Drug Delivery revenue is pod sales to Amgen for the Neulasta Onpro kit ($34.1M in 2025)
Relevance 55·Dependency 35·Confidence 95
Source evidence
“Substantially all of our Drug Delivery revenue consists of sales of pods to Amgen for use in the Neulasta® Onpro® kit”
Insulet produces pods for Amgen's Neulasta Onpro kit, a secondary revenue stream alongside the Omnipod diabetes business.
Relevance 55·Dependency 20·Confidence 95
Source evidence
“We also produce pods for Amgen for use in the Neulasta® Onpro® kit”
commercial insurance coverage
Demand Driver
Insulet offers financial assistance programs for users with commercial insurance, indicating payer coverage affects end-user demand economics.
Relevance 50·Dependency 40·Confidence 70
Source evidence
“including but not limited to financial assistance programs for users with commercial insurance”